Le Lézard
Classified in: Health, Business
Subject: DIV

Bruker Announces Quarterly Dividend


BILLERICA, Mass., Nov. 9, 2018 /PRNewswire/ -- Bruker Corporation (NASDAQ: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company's common stock. The dividend will be paid on December 21, 2018 to stockholders of record as of December 3, 2018.  

Bruker Corporation Logo

About Bruker Corporation (NASDAQ: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contact:
Miroslava Minkova
Director, Investor Relations & Corporate Development
Bruker Corporation                                                                   
T: +1 (978) 663 ? 3660, ext. 1479                                                                                   
E: [email protected]

SOURCE Bruker Corporation


These press releases may also interest you

at 09:50
Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American...

at 09:47
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...

at 09:45
Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty...

at 09:45
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech , a clinical stage pharmaceutical company with a...

at 09:41
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in...

at 09:35
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively. CancerVision and...



News published on and distributed by: